PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 121,809 shares, a drop of 16.5% from the November 30th total of 145,963 shares. Approximately 9.2% of the company’s shares are short sold. Based on an average daily volume of 217,670 shares, the short-interest ratio is currently 0.6 days. Based on an average daily volume of 217,670 shares, the short-interest ratio is currently 0.6 days. Approximately 9.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

PRFX has been the topic of a number of research reports. Wall Street Zen upgraded PainReform from a “strong sell” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

PainReform Stock Down 4.8%

PainReform stock opened at $0.64 on Friday. The firm has a market cap of $1.29 million, a PE ratio of 0.00 and a beta of 0.59. PainReform has a 52-week low of $0.61 and a 52-week high of $6.65. The company’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.27.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings results on Wednesday, October 1st. The company reported ($0.55) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.